23 items below
see also
Search Lymphoma in VitaminDWiki
Cancer - Leukemia
Overview Cancer and vitamin D
Web articles at the bottom of this page
Here are all of the Lymphoma and Vitamin D articles
- wiki page:
-
Non-Hodgkin’s lymphoma associated with poof Vitamin D receptor – Feb 2021
-
Improved long-term chemo survival if good Vitamin D (1.8 X better - Hodgkin Lymphoma) – Oct 2019
-
Non-Hodgkin Lymphoma 20 percent more likely if low UV – meta-analysis April 2019
-
Rates of some newly diagnosed Cancers increased with higher Vitamin D (217,000 Danes) – Jan 2019
-
Lymphoid cancer deaths cut in half with 400 IU of vitamin D and 1 gram of Calcium (WHI) – RCT Nov 2017
-
Vitamin D in haematological disorders and malignancies – Oct 2016
-
Cancer deaths strongly related to low vitamin D if sampled near time of diagnosis – Feb 2012
-
Lymphoma, leukemia etc, survival poor if low vitamin D – meta-analysis March 2015
-
Cancer (colon, breast, lymph) survival about 2X better with high level vitamin D – meta-analysis July 2014
-
Cancer survival 4 percent more likely with just a little more vitamin D (4 ng) - meta-analysis July 2014
-
Inflammatory Bowel Disease and Lymphoma – associated with low vitamin D in cats too – Jan 2014
-
Molecular Link between Vitamin D and Cancer Prevention – Oct 2013
-
Some childhood cancer 30% less likely in parts of California with more UVB – April 2013
-
The sun appears better at reducing incidence of some cancers than vitamin D – Dec 2012
-
Vitamin D and Risk of Rarer Cancers – Jan 2013
-
Hodgkin’s lymphoma and Vitamin D Receptor - June 2012
-
Hours of sun per week decreased probability of NH lymphoma by 32 percent – April 2012
-
Getting little UV is associated with 15 types of Cancer – Jan 2012
-
Cancer patients 64% less likely to die if have high level of vitamin D – Dec 2011
-
Living in areas with more UV decreased lymph problems by 42 percent – Aug 2011
-
Vitamin D Insufficiency and Prognosis in Non-Hodgkins Lymphoma
-
Mouse Lymphoedema and vitamin D - June 2010
Gene expression profile unveils diverse biological effect of serum VitaminD in Hodgkin's and Diffuse Large B-Cell Lymphoma - Nov 2020
Hematol Oncol. 2020 Nov 20. doi: 10.1002/hon.2827
Benedetta Donati 1, Angela Ferrari 2, Alessia Ruffini 3, Gloria Manzotti 1, Valentina Fragliasso 1, Francesco Merli 2, Magda Zanelli 4, Riccardo Valli 4, Stefano Luminari 2, Alessia Ciarrocchi 1
The primary function of 25(OH)VitaminD (VitD) is to control calcium, however recent evidence associated serum VitD deficiency to high aggressiveness and worse outcome in different type of malignancies including lymphomas and the reasons of such effect are to be defined.Here we investigated the association of VitD blood levels with gene expression in a retrospective cohort of 181 lymphomas (104 Diffuse Large B Cell Lymphomas and 77 classical Hodgkin's Lymphomas) of whom 116 with available gene expression profiles (52 DLBCLs and 64 cHLs respectively). In DLBCL VitD deficiency did not cause significant alteration in gene expression suggesting different mechanisms of action including a possible systemic effect or an effect on pharmacokinetics. By contrast, in cHLs VitD deficiency induced profound changes in the transcriptional program leading to the NF-κB-mediated activation of stress-protective and pro-survival pathways. Coherently, VitD signaling defined by Vitamin D Receptor (VDR) expression analysis, resulted highly activated in cHLs but not in DLBCLs. Even if preliminary these data represent the first evidence of a direct role of VitD in the biology of cHL and suggest a multimodality and disease-specific activity of this vitamin in Lymphomas.
25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it? - Aug 2018
Support Care Cancer. 2018 Aug;26(8):2825-2832. doi: 10.1007/s00520-018-4101-9. Epub 2018 Mar 6.
25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?
Djurasinović VT1,2, Mihaljević BS3,4, Šipetić Grujičić SB5, Ignjatović SD6, Trajković G7, Todorović-Balint MR3,4, Antić DA3,4, Bila JS3,4, Andjelić BM3,4, Jeličić JJ3, Vuković VM3, Nikolic AM5, Klek S8.
INTRODUCTION:
Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies.
METHODOLOGY:
Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics.
RESULTS: There were
- 37 (27.8%) patients with the severe 25(OH)D deficiency ≤ 25 nmol/l,
- 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and
- 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l.
None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D < 19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529).
CONCLUSION:
The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D < 19.6 nmol/l had a significantly shorter PFS.
Hodgkin Lymphoma is inversly related to altitude (more UVB, less HL) - Nov 2019
Ecological Evidence for Lower Risk of Lymphoma with Greater Exposure to Sunlight and Higher Altitude
High Alt Med Biol. 2019 Nov 25. doi: 10.1089/ham.2019.0054
Merrill RM1, Frutos AM1.
Merrill, Ray M., and Aaron M. Frutos. Ecological evidence for lower risk of lymphoma with greater exposure to sunlight and higher altitude. High Alt Med Biol. 20:000-000, 2019. Introduction: Sunlight exposure increases vitamin D-related immune modulation and motility of T lymphocytes. Blue light exposure from the sun can stimulate immune function and help promote healthy circadian rhythm. Hence, greater sunlight exposure may lower the risk of Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Altitude may also lower the risk of these cancers through an oxygen-related mechanism, and because cosmic radiation has less shield from the atmosphere at higher levels, it allows for radiation hormesis. Methods: An ecological study design was used, with county-level lymphoma, sunlight, altitude, urban residency, poverty, smoking, obesity, and leisure-time physical inactivity data for 16 cancer registries (607 counties) in the contiguous United States, 2012-2016. Relative rate estimates were derived from two-level mixed effects Poisson regression models. Results: Higher rates of NHL are associated with being older, male, and white. Higher rates of Hodgkin lymphoma are associated with ages 20 years and older, male, and white or black. The risk of NHL or Hodgkin lymphoma is lower among those living in poverty. Urban residency, smoking, obesity, and physical inactivity are not associated with these cancers. Both increased sunlight exposure and higher altitude are simultaneously associated with lower rates of Hodgkin lymphoma and NHL in adjusted models. The inverse association between sunlight and NHL is more pronounced with higher altitude. The inverse association between sunlight and Hodgkin lymphoma is only in altitudes below 500 m. Conclusions: Greater sunlight exposure and higher altitude are simultaneously associated with lower rates of Hodgkin lymphoma and NHL. The inverse associations are dependent on altitude, with the relationship only in lower altitudes for Hodgkin lymphoma and more pronounced in higher altitude for NHL.
Cancer - Lymphoma
21624 visitors, last modified 21 Nov, 2020,
Printer Friendly
PDF this page!
Follow this page for updates
See any problem with this page? Report it (FINALLY WORKS)
Search For a Page
see also
Search Lymphoma in VitaminDWiki
Cancer - Leukemia
Overview Cancer and vitamin D
Web articles at the bottom of this page
Here are all of the Lymphoma and Vitamin D articles
- wiki page:
- Non-Hodgkin’s lymphoma associated with poof Vitamin D receptor – Feb 2021
- Improved long-term chemo survival if good Vitamin D (1.8 X better - Hodgkin Lymphoma) – Oct 2019
- Non-Hodgkin Lymphoma 20 percent more likely if low UV – meta-analysis April 2019
- Rates of some newly diagnosed Cancers increased with higher Vitamin D (217,000 Danes) – Jan 2019
- Lymphoid cancer deaths cut in half with 400 IU of vitamin D and 1 gram of Calcium (WHI) – RCT Nov 2017
- Vitamin D in haematological disorders and malignancies – Oct 2016
- Cancer deaths strongly related to low vitamin D if sampled near time of diagnosis – Feb 2012
- Lymphoma, leukemia etc, survival poor if low vitamin D – meta-analysis March 2015
- Cancer (colon, breast, lymph) survival about 2X better with high level vitamin D – meta-analysis July 2014
- Cancer survival 4 percent more likely with just a little more vitamin D (4 ng) - meta-analysis July 2014
- Inflammatory Bowel Disease and Lymphoma – associated with low vitamin D in cats too – Jan 2014
- Molecular Link between Vitamin D and Cancer Prevention – Oct 2013
- Some childhood cancer 30% less likely in parts of California with more UVB – April 2013
- The sun appears better at reducing incidence of some cancers than vitamin D – Dec 2012
- Vitamin D and Risk of Rarer Cancers – Jan 2013
- Hodgkin’s lymphoma and Vitamin D Receptor - June 2012
- Hours of sun per week decreased probability of NH lymphoma by 32 percent – April 2012
- Getting little UV is associated with 15 types of Cancer – Jan 2012
- Cancer patients 64% less likely to die if have high level of vitamin D – Dec 2011
- Living in areas with more UV decreased lymph problems by 42 percent – Aug 2011
- Vitamin D Insufficiency and Prognosis in Non-Hodgkins Lymphoma
- Mouse Lymphoedema and vitamin D - June 2010
Gene expression profile unveils diverse biological effect of serum VitaminD in Hodgkin's and Diffuse Large B-Cell Lymphoma - Nov 2020
Hematol Oncol. 2020 Nov 20. doi: 10.1002/hon.2827
Benedetta Donati 1, Angela Ferrari 2, Alessia Ruffini 3, Gloria Manzotti 1, Valentina Fragliasso 1, Francesco Merli 2, Magda Zanelli 4, Riccardo Valli 4, Stefano Luminari 2, Alessia Ciarrocchi 1
The primary function of 25(OH)VitaminD (VitD) is to control calcium, however recent evidence associated serum VitD deficiency to high aggressiveness and worse outcome in different type of malignancies including lymphomas and the reasons of such effect are to be defined.Here we investigated the association of VitD blood levels with gene expression in a retrospective cohort of 181 lymphomas (104 Diffuse Large B Cell Lymphomas and 77 classical Hodgkin's Lymphomas) of whom 116 with available gene expression profiles (52 DLBCLs and 64 cHLs respectively). In DLBCL VitD deficiency did not cause significant alteration in gene expression suggesting different mechanisms of action including a possible systemic effect or an effect on pharmacokinetics. By contrast, in cHLs VitD deficiency induced profound changes in the transcriptional program leading to the NF-κB-mediated activation of stress-protective and pro-survival pathways. Coherently, VitD signaling defined by Vitamin D Receptor (VDR) expression analysis, resulted highly activated in cHLs but not in DLBCLs. Even if preliminary these data represent the first evidence of a direct role of VitD in the biology of cHL and suggest a multimodality and disease-specific activity of this vitamin in Lymphomas.
25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it? - Aug 2018
Support Care Cancer. 2018 Aug;26(8):2825-2832. doi: 10.1007/s00520-018-4101-9. Epub 2018 Mar 6.
25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?
Djurasinović VT1,2, Mihaljević BS3,4, Šipetić Grujičić SB5, Ignjatović SD6, Trajković G7, Todorović-Balint MR3,4, Antić DA3,4, Bila JS3,4, Andjelić BM3,4, Jeličić JJ3, Vuković VM3, Nikolic AM5, Klek S8.
INTRODUCTION:
Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies.
METHODOLOGY:
Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics.
RESULTS: There were
- 37 (27.8%) patients with the severe 25(OH)D deficiency ≤ 25 nmol/l,
- 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and
- 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l.
None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D < 19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529).
CONCLUSION:
The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D < 19.6 nmol/l had a significantly shorter PFS.
Hodgkin Lymphoma is inversly related to altitude (more UVB, less HL) - Nov 2019
Ecological Evidence for Lower Risk of Lymphoma with Greater Exposure to Sunlight and Higher Altitude
High Alt Med Biol. 2019 Nov 25. doi: 10.1089/ham.2019.0054
Merrill RM1, Frutos AM1.
Merrill, Ray M., and Aaron M. Frutos. Ecological evidence for lower risk of lymphoma with greater exposure to sunlight and higher altitude. High Alt Med Biol. 20:000-000, 2019. Introduction: Sunlight exposure increases vitamin D-related immune modulation and motility of T lymphocytes. Blue light exposure from the sun can stimulate immune function and help promote healthy circadian rhythm. Hence, greater sunlight exposure may lower the risk of Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Altitude may also lower the risk of these cancers through an oxygen-related mechanism, and because cosmic radiation has less shield from the atmosphere at higher levels, it allows for radiation hormesis. Methods: An ecological study design was used, with county-level lymphoma, sunlight, altitude, urban residency, poverty, smoking, obesity, and leisure-time physical inactivity data for 16 cancer registries (607 counties) in the contiguous United States, 2012-2016. Relative rate estimates were derived from two-level mixed effects Poisson regression models. Results: Higher rates of NHL are associated with being older, male, and white. Higher rates of Hodgkin lymphoma are associated with ages 20 years and older, male, and white or black. The risk of NHL or Hodgkin lymphoma is lower among those living in poverty. Urban residency, smoking, obesity, and physical inactivity are not associated with these cancers. Both increased sunlight exposure and higher altitude are simultaneously associated with lower rates of Hodgkin lymphoma and NHL in adjusted models. The inverse association between sunlight and NHL is more pronounced with higher altitude. The inverse association between sunlight and Hodgkin lymphoma is only in altitudes below 500 m. Conclusions: Greater sunlight exposure and higher altitude are simultaneously associated with lower rates of Hodgkin lymphoma and NHL. The inverse associations are dependent on altitude, with the relationship only in lower altitudes for Hodgkin lymphoma and more pronounced in higher altitude for NHL.
21624 visitors, last modified 21 Nov, 2020, |